
KRTX Stock Forecast & Price Target
KRTX Analyst Ratings
Bulls say
Karuna Therapeutics is a clinical-stage biopharmaceutical company that has a positive outlook due to their promising product candidate, KarXT, which is an oral modulator of muscarinic receptors targeted towards disabling neuropsychiatric conditions. The company's pipeline efforts are progressing well, with multiple near-term catalysts expected, including Phase 3 data for KarXT and near-term data for ambulatory blood pressure monitoring. The company also maintains a strong financial position, with a cash runway through 2026 and a well-defined commercialization strategy. With a unique drug profile and limited competition in its target markets, Karuna Therapeutics has the potential to become a major player in the neuropsychiatric space.
Bears say
Karuna Therapeutics is a clinical-stage biotech company that is pursuing novel neuropsychiatric therapies, but their lack of focus on environmental, social, and governance (ESG) initiatives may not bode well for long-term sustainability. While the company has promising clinical data and a deep management team, they are still a speculative investment with no current revenue-generating products and face potential risks in development and commercialization, including COVID-19 related delays.
This aggregate rating is based on analysts' research of Karuna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KRTX Analyst Forecast & Price Prediction
Start investing in KRTX
Order type
Buy in
Order amount
Est. shares
0 shares